Latest Insider Transactions at Selecta Biosciences Inc (SELB)
This section provides a real-time view of insider transactions for Selecta Biosciences Inc (SELB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SELECTA BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SELECTA BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+4.58%
|
-
|
|
May 26
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+12.86%
|
$60,000
$3.99 P/Share
|
|
May 26
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
926,170
+4.61%
|
$3,704,680
$4.0 P/Share
|
|
May 25
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.15%
|
$15,000
$3.48 P/Share
|
|
May 25
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
383,830
+2.06%
|
$1,151,490
$3.55 P/Share
|
|
May 24
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+10.16%
|
$37,500
$3.32 P/Share
|
|
May 24
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
590,000
+3.2%
|
$1,770,000
$3.38 P/Share
|
|
May 21
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,773,479
+13.85%
|
$8,320,437
$3.19 P/Share
|
|
May 07
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,629
+7.12%
|
$27,258
$2.77 P/Share
|
|
Mar 26
2021
|
Timothy C Barabe Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.24%
|
$40,000
$4.1 P/Share
|
|
Mar 18
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+9.26%
|
$40,000
$4.5 P/Share
|
|
Mar 17
2021
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
15,128
-14.74%
|
$60,512
$4.45 P/Share
|
|
Mar 17
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+10.2%
|
$40,000
$4.53 P/Share
|
|
Mar 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
5,461
-2.46%
|
$21,844
$4.26 P/Share
|
|
Mar 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,937
+4.69%
|
-
|
|
Feb 11
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,871
+30.43%
|
$0
$0.63 P/Share
|
|
Jan 04
2021
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+34.23%
|
-
|
|
Jan 04
2021
|
Bradford D. Dahms Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Jan 04
2021
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+39.69%
|
-
|
|
Jan 04
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+18.8%
|
-
|
|
Jan 04
2021
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+32.76%
|
-
|
|
Dec 14
2020
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+50.0%
|
$120,000
$3.24 P/Share
|
|
Dec 02
2020
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
3,323
-3.17%
|
$9,969
$3.35 P/Share
|
|
Dec 01
2020
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+9.46%
|
-
|
|
Oct 23
2020
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+19.21%
|
$60,000
$2.77 P/Share
|
|
Oct 23
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
994,488
+6.43%
|
$1,988,976
$2.71 P/Share
|
|
Oct 22
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,770,204
+11.6%
|
$3,540,408
$2.63 P/Share
|
|
Oct 21
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
880,000
+6.99%
|
$1,760,000
$2.5 P/Share
|
|
Oct 20
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
910,000
+7.75%
|
$1,820,000
$2.21 P/Share
|
|
Oct 19
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
759,500
+7.11%
|
$1,519,000
$2.36 P/Share
|
|
Oct 16
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
218,196
+2.33%
|
$436,392
$2.42 P/Share
|
|
Oct 09
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
276,703
+3.0%
|
$553,406
$2.0 P/Share
|
|
Oct 08
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
530,441
+5.76%
|
$530,441
$1.89 P/Share
|
|
Oct 07
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
654,953
+7.45%
|
$654,953
$1.65 P/Share
|
|
Oct 06
2020
|
Timothy C Barabe Director |
BUY
Open market or private purchase
|
Direct |
50,000
+22.62%
|
$50,000
$1.68 P/Share
|
|
Oct 06
2020
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,000,000
+21.08%
|
$2,000,000
$1.68 P/Share
|